雄激素受体通路信号抑制剂正在开发用于前列腺癌治疗
Sara Bleve1,2, Pier Vitale Nuzzo1, Abdul Baseet Arham3
1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
新型前列腺癌 (PC) 疗法向雄激素受体 (AR) 信号,以克服耐药性并减少副作用. 新兴的策略包括双极性激素治疗 (BAT),AR降解剂,以及针对抗性途径以改善治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 前列腺癌 (PC) 的进展,包括抵抗割的PC (CRPC),是由雄激素受体 (AR) 信号驱动的.
- 目前的雄激素剥夺疗法 (ADT) 和AR抑制剂可以提高生存率,但会导致不可避免的耐药性和毒性.
研究的目的:
- 审查AR信号在PC病变发生中的作用.
- 评估当前的AR向疗法及其局限性.
- 探索新的治疗策略,以克服耐药性和改善治疗模式.
主要方法:
- 在PC中AR信号的文献综述.
- 对当前和新兴AR向疗法的分析.
- 探索针对抵抗路径和AR降解的策略.
主要成果:
- 对AR抑制剂的耐药性是通过AR放大,突变和拼接变体产生的.
- 新的策略,如双极性激素治疗 (BAT),SARMs和AR降解剂 (PROTACs),提供了克服抗性的独特机制.
- 针对替代途径 (PI3K/AKT,EZH2) 和雄激素生物合成 (CYP11A1抑制剂) 是新兴的方法.
结论:
- 新的治疗策略正在转向针对前列腺癌的个性化药物.
- 这些新的方法旨在提高疗效并最大限度地降低系统性毒性.
- 克服AR驱动的抗性和谱系可塑性是持久治疗结果的关键.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
